Literature DB >> 18759277

Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis.

Chary López-Pedrera1, Maria José Cuadrado, Vanessa Herández, Paula Buendïa, Maria Angeles Aguirre, Nuria Barbarroja, Luis Arïstides Torres, José Manuel Villalba, Francisco Velasco, Munther Khamashta.   

Abstract

OBJECTIVE: Antiphospholipid antibodies (aPL) are closely related to the development of thrombosis, but the exact mechanism(s) leading to thrombotic events remains unknown. In this study, using proteomic techniques, we evaluated changes in protein expression of monocytes from patients with antiphospholipid syndrome (APS) related to the pathophysiology of the syndrome.
METHODS: Fifty-one APS patients were included. They were divided into 2 groups: patients with previous thrombosis, and patients with recurrent spontaneous abortion. As controls, we studied patients with thrombosis but without aPL, and age- and sex-matched healthy subjects.
RESULTS: The proteins that were more significantly altered among monocytes from APS patients with thrombosis (annexin I, annexin II, protein disulfide isomerase, Nedd8, RhoA proteins, and Hsp60) were functionally related to the induction of a procoagulant state as well as to autoimmune-related responses. Proteins reported to be connected to recurrent spontaneous abortion (e.g., fibrinogen and hemoglobin) were also determined to be significantly deregulated in APS patients without thrombosis. In vitro treatment with IgG fractions purified from the plasma of APS patients with thrombosis changed the pattern of protein expression of normal monocytes in the same way that was observed in vivo for monocytes from APS patients with thrombosis.
CONCLUSION: For the first time, proteomic analysis has identified novel proteins that may be involved in the pathogenic mechanisms of APS, thus providing potential new targets for pathogenesis-based therapies for the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18759277     DOI: 10.1002/art.23756

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  19 in total

Review 1.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

Review 2.  Myeloid Populations in Systemic Autoimmune Diseases.

Authors:  María Morell; Nieves Varela; Concepción Marañón
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

3.  Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis.

Authors:  Nadine Müller-Calleja; Anne Hollerbach; Svenja Ritter; Denise G Pedrosa; Dennis Strand; Claudine Graf; Christoph Reinhardt; Susanne Strand; Philippe Poncelet; John H Griffin; Karl J Lackner; Wolfram Ruf
Journal:  Blood       Date:  2019-08-21       Impact factor: 22.113

4.  Pathophysiological mechanisms in antiphospholipid syndrome.

Authors:  Brock E Harper; Rohan Wills; Silvia S Pierangeli
Journal:  Int J Clin Rheumtol       Date:  2011-04-01

5.  Immunomodulatory effects of therapeutic plasma exchange on monocytes in antiphospholipid syndrome.

Authors:  Anush Martirosyan; Martin Petrek; Amit Kishore; Gayane Manukyan
Journal:  Exp Ther Med       Date:  2016-06-08       Impact factor: 2.447

6.  Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways.

Authors:  Anastasia Lambrianides; Christopher J Carroll; Silvia S Pierangeli; Charis Pericleous; Ware Branch; Jurhee Rice; David S Latchman; Paul Townsend; David A Isenberg; Anisur Rahman; Ian P Giles
Journal:  J Immunol       Date:  2010-05-17       Impact factor: 5.422

7.  Transient pulmonary edema following adrenal infarction in a patient with primary anti-phospholipid syndrome.

Authors:  K Ozawa; K Tazawa; D Kishida; K Fukushima; M Matsuda; S Ikeda
Journal:  Clin Med Insights Case Rep       Date:  2012-12-04

8.  Purified IgG from patients with obstetric but not IgG from non-obstetric antiphospholipid syndrome inhibit trophoblast invasion.

Authors:  Katie Poulton; Vera M Ripoll; Charis Pericleous; Pier Luigi Meroni; Maria Gerosa; Yiannis Ioannou; Anisur Rahman; Ian P Giles
Journal:  Am J Reprod Immunol       Date:  2014-12-02       Impact factor: 3.886

9.  Thrombotic antiphospholipid syndrome shows strong haplotypic association with SH2B3-ATXN2 locus.

Authors:  Eguzkine Ochoa; Mikel Iriondo; Ana Bielsa; Guillermo Ruiz-Irastorza; Andone Estonba; Ana M Zubiaga
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

10.  Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome.

Authors:  Vera M Ripoll; Anastasia Lambrianides; Silvia S Pierangeli; Katie Poulton; Yiannis Ioannou; Wendy E Heywood; Kevin Mills; David S Latchman; David A Isenberg; Anisur Rahman; Ian P Giles
Journal:  Blood       Date:  2014-10-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.